Search results for " Fibrinogen"

showing 10 items of 53 documents

A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration

2015

Genome-wide association studies have previously identified 23 genetic loci associated with circulating fibrinogen concentration. These studies used HapMap imputation and did not examine the X-chromosome. 1000 Genomes imputation provides better coverage of uncommon variants, and includes indels. We conducted a genome-wide association analysis of 34 studies imputed to the 1000 Genomes Project reference panel and including similar to 120 000 participants of European ancestry (95 806 participants with data on the X-chromosome). Approximately 10.7 million single-nucleotide polymorphisms and 1.2 million indels were examined. We identified 41 genome-wide significant fibrinogen loci ; of which, 18 …

AdultMale0301 basic medicineNetherlands Twin Register (NTR)Single-nucleotide polymorphismGenome-wide association studyBiologyPolymorphism Single NucleotideWhite People03 medical and health sciencesINDEL MutationGenetics/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_Humans1000 Genomes ProjectInternational HapMap ProjectIndelMolecular BiologyGenetics (clinical)ComputingMilieux_MISCELLANEOUSAgedGenetic associationAged 80 and overGeneticsAssociation Studies ArticlesFibrinogen[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyGeneral MedicineMiddle AgedGenetic architecture030104 developmental biologyGenetic LociFemaleGENOME-WIDE ASSOCIATION ; C-REACTIVE PROTEIN ; CARDIOVASCULAR-DISEASE ; CIRCULATING FIBRINOGEN ; GENETIC ARCHITECTURE ; VARIANTS ; DESIGN ; HEMOSTASIS ; RESOURCE ; HEALTHImputation (genetics)Genome-Wide Association Study
researchProduct

The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism

2019

Renal impairment, a source of chronic hypercoagulability[1][1] and inflammation,[2][2] is known to reduce the specificity of the D-dimer test in the diagnosis of venous thromboembolism (VTE).[3][3] This leads to many false positives in such patients and consequently to additional costs, as well as

AdultMalemedicine.medical_specialtyComputed Tomography AngiographyRenal functionSensitivity and SpecificityFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineText miningInternal medicineD-dimermedicineFalse positive paradoxHumansFalse Positive ReactionsProspective StudiesRenal InsufficiencyProspective cohort studyOnline Only ArticlesComputed tomography angiographyAgedProbabilityVenous Thrombosismedicine.diagnostic_testbusiness.industryHematologyVenous ThromboembolismMiddle AgedCardiologyFemalebusinessPulmonary EmbolismVenous thromboembolismAlgorithms030215 immunologyGlomerular Filtration RateHaematologica-the Hematology Journal
researchProduct

Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection

2021

Summary Objective To determine the incidence, characteristics, and risk factors of pulmonary embolism (PE) among patients hospitalized for COVID-19. Patients and Methods We performed a prospective observational study of a randomly selected cohort of consecutive patients hospitalized for COVID-19 infection between March 8, 2020 through April 25, 2020. All eligible patients underwent a computed tomography pulmonary angiography independently of their PE clinical suspicion and were pre-screened for a baseline elevated D-dimer level. Results 119 patients were randomly selected from the 372 admitted to one tertiary hospital in Valencia (Spain) for COVID-19 infection during the period of study. Se…

Male0301 basic medicineCTPA Computed tomography pulmonary angiographyAUC-ROC Area under curve ROCPCR polymerase chain reaction0302 clinical medicineRisk FactorsspO2 Oxygen saturationIL6 Interleukin-6Pulmonary angiographySD Standard deviationMedicineProspective Studies030212 general & internal medicineProspective cohort studyComputed tomographyFramingham Risk ScoreIncidenceIncidence (epidemiology)RV Right ventricleHazard ratioVenous ThromboembolismMiddle AgedAo Aortic arteryPulmonary embolismCXR chest X-rayHospitalizationInfectious DiseasesCohortCRP C-reactive proteinFemalePA Pulmonary artery trunkMicrobiology (medical)medicine.medical_specialty030106 microbiologysPESI Simplified Pulmonary Embolism Severity IndexBMI Body mass indexPE Pulmonary embolismLV Left ventricleVTE Venous thromboembolismFibrin Fibrinogen Degradation Products03 medical and health sciencesInternal medicineHumansICU Intensive care unitsACE2 Angiotensin converting enzyme-2AgedInflammationLDH Lactate dehydrogenaseSARS-CoV-2 Severe acute respiratory syndrome coronavirus 2CI Confidence intervalbusiness.industryPulmonary embolismCOVID-19AnticoagulantsThrombosisRR Respiratory ratemedicine.diseaseConfidence intervalCHOD CRP concentration + Heart rate + Oxygen saturation + D-dimer levelsSpainHR Hazard RatioCommentarybusinessJournal of Infection
researchProduct

How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?

2009

The current approach for deciding the duration of vitamin K antagonist (VKA) treatment after an episode of venous thrombo-embolism (VTE) is mainly based on the characteristic of the index event (3 months or longer in case of unknown/persistent risk factors, 3 months or less in case of removable causes). However, the length of anticoagulation should be tailored on the patient's risk for recurrent thrombosis as well as for bleeding, but such 'time for decision' is often unclear and the optimal duration of VKA remains debatable. The presence of persistent residual vein thrombosis and increased D-dimer levels after stopping therapy are predictors for recurrent deep vein thrombosis (DVT). Manage…

medicine.medical_specialtyTime FactorsVitamin Kmedicine.drug_classDeep veinRisk AssessmentDrug Administration ScheduleRecurrent deep vein thrombosisSettore MED/15 - Malattie Del SangueFibrin Fibrinogen Degradation ProductsFibrinolytic AgentsRecurrenceNeoplasmsmedicineHumansVenous ThrombosisFirst episodebusiness.industryVascular diseaseAnticoagulantVitaminsHematologyVitamin K antagonistmedicine.diseaseThrombosisduration anticoagulants venous thromboembolismSurgeryVenous thrombosismedicine.anatomical_structurebusinessBiomarkersBritish Journal of Haematology
researchProduct

Il fibrinogeno come predittore di mortalita’ in un follow-up di 42 mesi post-infarto miocardico acuto

2002

Il fibrinogeno mortalita’ post-infarto miocardico acuto
researchProduct

Laboratory control of minimal heparinization during haemodialysis in patients with a risk of haemorrhage

1994

Abstract For patients undergoing dialysis with a high risk of haemorrhage there is no standardized procedure for anticoagulation during extracorporeal circulation. Minimal heparinization with a dose equivalent to half that used for chronic haemodialysis was employed in 49 patients (125 haemodialyses) performed after operative interventions (83.3%), after haemorrhagic events (5.2%) and after invasive investigations (11.5%). Using a biocompatible membrane and a low molecular weight heparin (bolus dose 500-1300 U; continuous infusion 100-400 U) it was possible to complete haemodialysis in 74 cases (Group 0) without clots appearing in the venous bubble trap of the tubing system. In 30 cases (Gr…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAntithrombin IIILow molecular weight heparinHemorrhageFibrin Fibrinogen Degradation ProductsClinical ProtocolsRenal DialysisRisk FactorsmedicineHumansIn patientRisk factorDialysisAgedMonitoring PhysiologicDose-Response Relationship Drugbusiness.industryAnticoagulantExtracorporeal circulationHematologyGeneral MedicineHeparinHeparin Low-Molecular-WeightMiddle AgedAntifibrinolytic AgentsSurgeryFemaleHemodialysisbusinessPeptide Hydrolasesmedicine.drugBlood Coagulation & Fibrinolysis
researchProduct

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The "Circulating Wound" Model.

2021

Current cytoreductive and antithrombotic strategies in MPNs are mostly based on cell counts and on patient’s demographic and clinical history. Despite the numerous studies conducted on platelet function and on the role of plasma factors, an accurate and reliable method to dynamically quantify the hypercoagulability states of these conditions is not yet part of clinical practice. Starting from our experience, and after having sifted through the literature, we propose an in-depth narrative report on the contribution of the clonal platelets of MPNs—rich in tissue factor (TF)—in promoting a perpetual procoagulant mechanism. The whole process results in an unbalanced generation of thrombin and i…

Blood PlateletsQH301-705.5platelet functionMPNInflammationReviewDiseaseBioinformaticsFibrinogenModels BiologicalCatalysisPAR receptorLeukemia Myeloid Chronic Atypical BCR-ABL NegativeInorganic ChemistryTissue factorThrombinAntithromboticmedicineAnimalsHumansThrombophiliaPlateletPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyPAR receptorsbusiness.industryOrganic ChemistryThrombinGeneral MedicineComputer Science ApplicationsChemistryReceptors FibrinogenCoagulationthrombin generationBiological Assayfibrinogenmedicine.symptombusinessmedicine.drugInternational journal of molecular sciences
researchProduct

Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility

2020

Abstract Background The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. Here, we retrospectively evaluated and integrated laboratory parameters of 45 elderly subjects from a long-term care facility with Sars-CoV-2 outbreak and spread, to identify potential common patterns of systemic response able to better stratify patients’ clinical course and outcome. Methods Baseline white blood cells, granulocytes’, lymphocytes’, and platelets’ counts, hemoglobin, total iron, ferritin, D-dimer, and interleukin-6 concentration were used to generate a …

Malemedicine.medical_specialtyLymphocyteIronlcsh:MedicineDiseaseMonocyteGeneral Biochemistry Genetics and Molecular BiologyMonocytesFibrin Fibrinogen Degradation ProductsLeukocyte CountLong-term care facilitieInternal medicineD-dimermedicineHumansLymphocytesAgedRetrospective StudiesAged 80 and overbiologybusiness.industryPlatelet CountLong-term care facilitiesClinical outcomeSARS-CoV-2MonocyteResearchlcsh:RCOVID-19Retrospective cohort studyGeneral MedicineBiomarkerMiddle Agedmedicine.diseasePrognosisLong-Term CareFerritinPneumoniamedicine.anatomical_structureTreatment OutcomeD-dimerbiology.proteinFemaleLymphocyteHemoglobinbusinessBiomarkers
researchProduct

Deferral of assessment of pulmonary embolism

2007

We evaluated a simplified algorithm for safely postponing diagnostic imaging for pulmonary embolism (PE). At the index visit, patients were identified as being at high or low risk of PE; the former received full dosage low molecular weight heparin while the latter were left untreated until performance of diagnostic imaging (max 72 hours). During this period, no thromboembolic events occurred in low-risk patients (0/211, 0.% [upper 95% CI 0.9%]); only one event occurred in those at high-risk (1/125, 0.8% [upper 95% CI, 1.2]). Our study demonstrates that diagnostic imaging for PE can be safely deferred for up to 3 days.

AdultMaleRiskmedicine.medical_specialtyTime Factorsmedicine.drug_classLow molecular weight heparinThrombophiliaVentilation/perfusion ratioFibrin Fibrinogen Degradation ProductsPredictive Value of TestsThromboembolismD-dimerPrevalenceVentilation-Perfusion RatiomedicineHumansThrombophiliaAgedAged 80 and overVenous Thrombosisbusiness.industryRespiratory diseaseAnticoagulantsHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryHospitalizationVenous thrombosisEarly DiagnosisTreatment OutcomePredictive value of testsFemalePulmonary EmbolismbusinessTomography Spiral ComputedAlgorithmsHaematologica
researchProduct

Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism…

2021

Male2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Unfractionated heparinLetter to the Editors-in-ChiefCohort StudiesFibrin Fibrinogen Degradation ProductsInternal medicineD-dimerHumansMedicineIn patientHeparinbusiness.industryPulmonary embolismCOVID-19HematologyHeparinmedicine.diseaseCOVID-19 Drug TreatmentPulmonary embolismRadiological weaponD-dimerbusinessCohort studymedicine.drug
researchProduct